Efficacy and safety of rechallenge [ 177 Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).

Florian RosarJoelle SchulerCaroline BurgardArne BlickleMark BartholomäStephan MausSven PettoFadi KhreishAndrea SchaeferSamer Ezziddin

Published in: European journal of nuclear medicine and molecular imaging (2024)

Lu]Lu-PSMA-617 RLT rechallenge is associated with significant PSA response and encouraging survival outcome as well as a very favourable safety profile and should therefore be considered as a straight-forward treatment option in mCRPC patients, who previously benefited from PSMA-RLT.

Keyphrases

pet ct
pet imaging
prostate cancer
computed tomography
rheumatoid arthritis
radical prostatectomy
systemic lupus erythematosus
combination therapy
ulcerative colitis
virtual reality